Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Infection-related arthritis
•
General Rheumatology
•
Infectious Disease
How do you approach evaluation for indolent infection in patients with chronic erosive arthropathy?
Related Questions
In patients taking biologics who are planning joint replacement and are known MRSA carriers do you perform decolonization prior to surgery?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
How do you approach endocarditis prophylaxis for patients with rheumatic diseases undergoing invasive dental surgery and no history of joint replacement?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
What is the optimal timing for Zoster vaccine administration for a patient who recently recovered from herpes zoster infection and is now planning to start B-cell depletion therapy?
How do you approach management of patients with active RA and recurrent non-severe C.diff?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
When is it safe to resume DMARDs in a patient who was diagnosed with active TB and started on treatment?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
